RTI Surgical has recently taken a significant step in enhancing its capabilities in regenerative medicine through the strategic acquisition of Collagen Solutions. This move is set to expand RTI’s portfolio in biomaterials, which further establishes the company as a leader in the biomedical sector. B
The market for gene therapies is predicted to surge from $9 billion in 2023 to $23.9 billion in 2028, according to MarketsandMarkets. With such rapid growth, it has become increasingly evident that having an effective analytical testing strategy is crucial for the successful development and
In a significant move to bolster its service offerings, Simtra BioPharma Solutions has announced a $14 million investment aimed at enhancing its Antibody-Drug Conjugates (ADCs) development and manufacturing capabilities. Set to establish a new clinical suite at its Halle/Westfalen, Germany site,
The U.S. government, through the Centers for Medicare and Medicaid Services (CMS), has unveiled fresh modifications to its drug price negotiation process under Medicare. These changes aim to enhance transparency and efficacy as the second round of talks with pharmaceutical manufacturers looms on
The biopharmaceutical industry is on the cusp of a revolutionary transformation that promises to redefine its future trajectory. While Biopharma 4.0 brought about significant advancements in digitization and smart manufacturing, its successor, Biopharma 5.0, aims to integrate human creativity,
The biopharmaceutical industry is increasingly recognizing sustainability as a critical component of its future success. According to Cytiva’s 2024 Global Biopharma Sustainability Review, which surveyed 800 industry professionals from 18 countries, sustainability has shifted from a secondary c
Verdot, a leader in downstream purification solutions for the biopharmaceutical industry, is making headlines with its ambitious plans to expand manufacturing capacity by 150%. This development is taking place in Riom, France — a location with historical significance for the company. The extensive p
The long-term commercial supply agreement between Lonza and Vertex Pharmaceuticals marks a pivotal moment in the field of gene therapy, promising significant advancements for patients suffering from sickle cell disease (SCD) and beta-thalassemia. This collaboration focuses on the production of
Multiply Labs and Legend Biotech have announced a strategic collaboration aimed at transforming cell therapy production through advanced robotics. This partnership between Multiply Labs, renowned for its innovative automation systems, and Legend Biotech, celebrated for its role in developing the
Sutro Biopharma Inc. (NASDAQ: STRO) has experienced a dynamic market journey characterized by several key financial metrics, analyst ratings, and insider transactions. This article delves into the company’s recent market performance, aiming to provide investors with a comprehensive understanding of
